Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Oncology / 腫瘤醫學研究所
  4. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
 
  • Details

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer

Journal
American Journal of Respiratory and Critical Care Medicine
Journal Volume
178
Journal Issue
8
Pages
847-853
Date Issued
2008
Author(s)
Wu J.-Y.
CHONG-JEN YU  
CHIH-HSIN YANG  
SHANG-GIN WU  
Chiu Y.-H.
Gow C.-H.
YEUN-CHUNG CHANG  
Hsu Y.-C.
Wei P.-F.
JIN-YUAN SHIH  
PAN-CHYR YANG  
DOI
10.1164/rccm.200803-389OC
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-54049153188&doi=10.1164%2frccm.200803-389OC&partnerID=40&md5=2f5ff30e8c58660b55d636af009347e6
https://scholars.lib.ntu.edu.tw/handle/123456789/495113
Abstract
Rationale: Gefitinib is effective in treating patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in exon 21 are the best-documented EGFR mutations that are associated with effective gefitinib responsiveness. Objectives: To clarify the influence of gefitinib timing, we conducted a study to compare the outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R. Methods: We surveyed the clinical data and mutational studies of patients with NSCLC with EGFR mutations in the National Taiwan University Hospital (Taipei, Taiwan). Measurements and Main Results: Three hundred and twenty-eight patients, who received gefitinib for stage IIIb or IV NSCLC, were adequately sequenced for EGFR mutations; 192 patients had mutant EGFR, including 77 patients with exon 19 deletions and 75 patients with L858R. The 152 patients with exon 19 deletions or L858R and who were receiving gefitinib were classified into a chemonaive group (91 patients) or a chemotherapy-treated group (61 patients). Chemonaive status before gefitinib and female sex were associated with clinical response to gefitinib (P = 0.006 and 0.053, respectively). Neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between these two groups (P = 0.207 and 0.804, respectively). Clinical response to gefitinib was the only factor associated with better overall survival (P = 0.001). Conclusions: This study suggests that gefitinib is effective in patients with EGFR mutations. The gefitinib response rate in chemonaive patients is higher than in chemotherapy-treated patients; however, there is no difference in overall survival.
SDGs

[SDGs]SDG3

Other Subjects
epidermal growth factor; gefitinib; mutant protein; DNA; epidermal growth factor receptor; gefitinib; protein kinase inhibitor; quinazoline derivative; adult; aged; article; cancer chemotherapy; cancer growth; cancer staging; cancer survival; controlled study; drug efficacy; exon; female; gene deletion; gene mutation; health survey; human; lung non small cell cancer; major clinical study; male; priority journal; treatment outcome; treatment response; comparative study; drug antagonism; follow up; genetics; lung tumor; metabolism; middle aged; mortality; mutation; polymerase chain reaction; retrospective study; survival rate; Taiwan; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Receptor, Epidermal Growth Factor; Retrospective Studies; Survival Rate; Taiwan
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science